Novo Nordisk A/S

Novo Nordisk A/S (NYSE: NVO) is an international healthcare company focused on diabetes care. It is also involved in the research, development, production, and marketing of pharmaceutical products.

As per our previous US Technical Analysis report published on ‘NVO’ on 25^th Feb, 2025, Kalkine provided an ‘Buy’ stance on the stock at USD 90.59 based on technical analysis and the stock price has now moved down by ~30.51% since then.

Noted below are the details of support and resistance levels provided in our previous report:

Daily Chart

Considering a volatile market condition led by recent tariffs escalation from United States and subsequent retaliation, jolted supply chain, recession fear, higher interest rate and geopolitical disruption, a ‘Sell’ rating is assigned to the ‘NVO’ at the current market price of USD 62.95 as of April 08,2025 at 08:01 AM PDT. 

Note: This report may be updated with details around fundamental and technical analysis, price chart in due course, as appropriate.

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is April 08,2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.